Published in Rejuvenation Res on August 01, 2013
Glycolysis and the significance of lactate in traumatic brain injury. Front Neurosci (2015) 0.93
The rate of change in declining steroid hormones: a new parameter of healthy aging in men? Oncotarget (2016) 0.83
Off-label use of hormones as an antiaging strategy: a review. Clin Interv Aging (2014) 0.82
Dehydroepiandrosterone Activation of G-protein-coupled Estrogen Receptor Rapidly Stimulates MicroRNA-21 Transcription in Human Hepatocellular Carcinoma Cells. J Biol Chem (2015) 0.81
Carbonyl stress in aging process: role of vitamins and phytochemicals as redox regulators. Aging Dis (2013) 0.78
Estrogen Regulation of Fetal Adrenal Cortical Zone-Specific Development in the Nonhuman Primate Impacts Adrenal Production of Androgen and Cortisol and Response to ACTH in Females in Adulthood. Endocrinology (2016) 0.76
Higher serum dehydroepiandrosterone sulfate protects against the onset of depression in the elderly: Findings from the English Longitudinal Study of Aging (ELSA). Psychoneuroendocrinology (2015) 0.76
Effects of dietary restriction on adipose mass and biomarkers of healthy aging in human. Aging (Albany NY) (2016) 0.75
The Association between Dehydroepiandrosterone Sulfate (DHEA-S) and Bone Mineral Density in Korean Men and Women. J Bone Metab (2017) 0.75
Uptake and metabolism of sulphated steroids by the blood-brain barrier in the adult male rat. J Neurochem (2017) 0.75
Guideline for the prevention of falls in older persons. American Geriatrics Society, British Geriatrics Society, and American Academy of Orthopaedic Surgeons Panel on Falls Prevention. J Am Geriatr Soc (2001) 11.09
Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol (1994) 10.03
The projected effect of risk factor reduction on Alzheimer's disease prevalence. Lancet Neurol (2011) 8.15
DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med (2006) 7.90
Prevalence and severity of cognitive impairment with and without dementia in an elderly population. Lancet (1997) 4.39
The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev (2005) 3.11
Circulating androgen levels and self-reported sexual function in women. JAMA (2005) 2.40
Endogenous sex hormones and glucose tolerance status in postmenopausal women. J Clin Endocrinol Metab (2007) 2.29
A prospective study of dehydroepiandrosterone sulfate, mortality, and cardiovascular disease. N Engl J Med (1986) 2.18
Dehydroepiandrosterone replacement in women with adrenal insufficiency. N Engl J Med (1999) 2.13
Older patients in the emergency department: a review. Ann Emerg Med (2010) 2.06
Anabolic deficiency in men with chronic heart failure: prevalence and detrimental impact on survival. Circulation (2006) 2.00
Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J Clin Endocrinol Metab (1994) 1.79
Endogenous androgen levels and cardiovascular risk profile in women across the adult life span. Menopause (2007) 1.70
The approach to the adult with newly diagnosed adrenal insufficiency. J Clin Endocrinol Metab (2009) 1.61
Dehydroepiandrosterone replacement in aging humans. J Clin Endocrinol Metab (1999) 1.60
Dehydroepiandrosterone treatment of midlife dysthymia. Biol Psychiatry (1999) 1.57
Effect of DHEA on abdominal fat and insulin action in elderly women and men: a randomized controlled trial. JAMA (2004) 1.51
Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEAge Study to a sociobiomedical issue. Proc Natl Acad Sci U S A (2000) 1.51
Is dehydroepiandrosterone a hormone? J Endocrinol (2005) 1.46
Remaining lifetime and absolute 10-year probabilities of osteoporotic fracture in Swiss men and women. Osteoporos Int (2008) 1.45
The effect of six months treatment with a 100 mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex steroids, body composition and muscle strength in age-advanced men and women. Clin Endocrinol (Oxf) (1998) 1.45
Liquid chromatography-tandem mass spectrometry assay for androstenedione, dehydroepiandrosterone, and testosterone with pediatric and adult reference intervals. Clin Chem (2010) 1.44
Sexual hormones in human skin. Horm Metab Res (2007) 1.43
Linking age-related changes in skeletal muscle mass and composition with metabolism and disease. J Nutr Health Aging (2006) 1.39
Endogenous levels of dehydroepiandrosterone sulfate, but not other sex hormones, are associated with depressed mood in older women: the Rancho Bernardo Study. J Am Geriatr Soc (1999) 1.37
Prevalence of dementia in the elderly in Europe. Eur Neuropsychopharmacol (2005) 1.33
Effect of DHEAS on skeletal muscle over the life span: the InCHIANTI study. J Gerontol A Biol Sci Med Sci (2004) 1.32
Dehydroepiandrosterone activates endothelial cell nitric-oxide synthase by a specific plasma membrane receptor coupled to Galpha(i2,3). J Biol Chem (2002) 1.22
Dehydroepiandrosterone combined with exercise improves muscle strength and physical function in frail older women. J Am Geriatr Soc (2010) 1.22
Postmenopausal dehydroepiandrosterone administration increases free insulin-like growth factor-I and decreases high-density lipoprotein: a six-month trial. Fertil Steril (1998) 1.20
Dehydroepiandrosterone (DHEA)--a precursor steroid or an active hormone in human physiology. J Sex Med (2011) 1.16
Dehydroepiandrosterone sulfate levels are associated with more favorable cognitive function in women. J Clin Endocrinol Metab (2007) 1.14
Effects of DHEA replacement on bone mineral density and body composition in elderly women and men. Clin Endocrinol (Oxf) (2000) 1.14
Phase I study of STX 64 (667 Coumate) in breast cancer patients: the first study of a steroid sulfatase inhibitor. Clin Cancer Res (2006) 1.10
Mitotic and neurogenic effects of dehydroepiandrosterone (DHEA) on human neural stem cell cultures derived from the fetal cortex. Proc Natl Acad Sci U S A (2004) 1.10
Salivary cortisol and DHEA: association with measures of cognition and well-being in normal older men, and effects of three months of DHEA supplementation. Psychoneuroendocrinology (2001) 1.09
Double-blind treatment of major depression with dehydroepiandrosterone. Am J Psychiatry (1999) 1.08
Dehydroepiandrosterone monotherapy in midlife-onset major and minor depression. Arch Gen Psychiatry (2005) 1.07
Dehydroepiandrosterone sulfate does not predict cardiovascular death in postmenopausal women. The Rancho Bernardo Study. Circulation (1995) 1.07
Oral dehydroepiandrosterone for adrenal androgen replacement: pharmacokinetics and peripheral conversion to androgens and estrogens in young healthy females after dexamethasone suppression. J Clin Endocrinol Metab (1998) 1.06
Altered salivary dehydroepiandrosterone levels in major depression in adults. Biol Psychiatry (2000) 1.06
Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy. Menopause (2009) 1.06
Dehydroepiandrosterone sulfate and psychiatric measures in a frail, elderly residential care population. Biol Psychiatry (2000) 1.05
Reduction of atherosclerosis by administration of dehydroepiandrosterone. A study in the hypercholesterolemic New Zealand white rabbit with aortic intimal injury. J Clin Invest (1988) 1.05
The influence of exercise on brain aging and dementia. Biochim Biophys Acta (2011) 1.04
Effects of dehydroepiandrosterone replacement therapy on bone mineral density in older adults: a randomized, controlled trial. J Clin Endocrinol Metab (2006) 1.04
Low dehydroepiandrosterone and ischemic heart disease in middle-aged men: prospective results from the Massachusetts Male Aging Study. Am J Epidemiol (2001) 1.03
Clinical review: DHEA replacement for postmenopausal women. J Clin Endocrinol Metab (2011) 1.02
Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women. J Clin Endocrinol Metab (1997) 1.02
Dehydroepiandrosterone, dehydroepiandrosterone sulfate, obesity, waist-hip ratio, and noninsulin-dependent diabetes in postmenopausal women: the Rancho Bernardo Study. J Clin Endocrinol Metab (1996) 1.00
Dehydroepiandrosterone stimulates nitric oxide release in vascular endothelial cells: evidence for a cell surface receptor. Steroids (2004) 1.00
Dehydroepiandrosterone (DHEA) treatment of depression. Biol Psychiatry (1997) 1.00
Replacement of DHEA in aging men and women. Potential remedial effects. Ann N Y Acad Sci (1995) 0.99
Aromatase in bone cell: association with osteoporosis in postmenopausal women. J Steroid Biochem Mol Biol (1995) 0.99
Opposing effects of DHEA replacement in elderly subjects on declarative memory and attention after exposure to a laboratory stressor. Psychoneuroendocrinology (1998) 0.99
Effect of dehydroepiandrosterone replacement on insulin sensitivity and lipids in hypoadrenal women. Diabetes (2005) 0.98
The effect of dehydroepiandrosterone supplementation to symptomatic perimenopausal women on serum endocrine profiles, lipid parameters, and health-related quality of life. J Clin Endocrinol Metab (1999) 0.98
Effect of 1-year oral administration of dehydroepiandrosterone to 60- to 80-year-old individuals on muscle function and cross-sectional area: a double-blind placebo-controlled trial. Arch Intern Med (2003) 0.97
Metabolic effects of dehydroepiandrosterone replacement therapy in postmenopausal women. Eur J Endocrinol (2001) 0.97
Dehydroepiandrosterone, glucose-6-phosphate dehydrogenase, and longevity. Ageing Res Rev (2004) 0.97
Dehydroepiandrosterone modulates endothelial nitric oxide synthesis via direct genomic and nongenomic mechanisms. Endocrinology (2003) 0.97
Effect of dehydroepiandrosterone supplementation on bone mineral density, bone markers, and body composition in older adults: the DAWN trial. Osteoporos Int (2007) 0.96
A prospective study of dehydroepiandrosterone sulfate and cognitive function in an older population: the Rancho Bernardo Study. J Am Geriatr Soc (1994) 0.95
Biotransformation of oral dehydroepiandrosterone in elderly men: significant increase in circulating estrogens. J Clin Endocrinol Metab (1999) 0.94
DHEA therapy for women: effect on sexual function and wellbeing. Hum Reprod Update (2007) 0.94
DHEA protects against visceral obesity and muscle insulin resistance in rats fed a high-fat diet. Am J Physiol (1997) 0.93
Changes in serum DHEA and eleven of its metabolites during 12-month percutaneous administration of DHEA. J Steroid Biochem Mol Biol (2008) 0.92
Increases in bone mineral density in response to oral dehydroepiandrosterone replacement in older adults appear to be mediated by serum estrogens. J Clin Endocrinol Metab (2008) 0.92
Relationship between serum sex steroids and Aging Male Symptoms score and International Index of Erectile Function. Urology (2005) 0.92
Predictors of bone mineral density in aging healthy men varies by skeletal site. Calcif Tissue Int (2002) 0.91
Anti-obesity effect of two different levels of dehydroepiandrosterone in lean and obese middle-aged female Zucker rats. Int J Obes (1986) 0.91
Dehydroepiandrosterone retards atherosclerosis formation through its conversion to estrogen: the possible role of nitric oxide. Arterioscler Thromb Vasc Biol (2000) 0.91
Effects of dehydroepiandrosterone supplementation on cognitive function and quality of life: the DHEA and Well-Ness (DAWN) Trial. J Am Geriatr Soc (2008) 0.91
Dehydroepiandrosterone replacement administration: pharmacokinetic and pharmacodynamic studies in healthy elderly subjects. J Clin Endocrinol Metab (2000) 0.90
DHEA-S levels and cardiovascular disease mortality in postmenopausal women: results from the National Institutes of Health--National Heart, Lung, and Blood Institute (NHLBI)-sponsored Women's Ischemia Syndrome Evaluation (WISE). J Clin Endocrinol Metab (2010) 0.89
Metabolic effects of 12-month percutaneous dehydroepiandrosterone replacement therapy in postmenopausal women. J Endocrinol (1996) 0.89
A randomized controlled trial of dehydroepiandrosterone in postmenopausal women with fibromyalgia. J Rheumatol (2005) 0.89
Dehydroepiandrosterone augmentation in the management of negative, depressive, and anxiety symptoms in schizophrenia. Arch Gen Psychiatry (2003) 0.88
Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women. Menopause (2009) 0.88
Cancer prevention with dehydroepiandrosterone and non-androgenic structural analogs. J Cell Biochem Suppl (1995) 0.88
Additive benefit of higher testosterone levels and vitamin D plus calcium supplementation in regard to fall risk reduction among older men and women. Osteoporos Int (2008) 0.87
Lack of dehydroepiandrosterone effect on a combined endurance and resistance exercise program in postmenopausal women. J Clin Endocrinol Metab (2007) 0.87
The safety of 52 weeks of oral DHEA therapy for postmenopausal women. Maturitas (2009) 0.86
Dehydroepiandrosterone improves murine osteoblast growth and bone tissue morphometry via mitogen-activated protein kinase signaling pathway independent of either androgen receptor or estrogen receptor. J Mol Endocrinol (2007) 0.86
Dehydroepiandrosterone replacement therapy in older adults: 1- and 2-y effects on bone. Am J Clin Nutr (2009) 0.85
Dehydroepiandrosterone sulfate and cognitive function in the elderly: The InCHIANTI Study. J Endocrinol Invest (2009) 0.85
Dehydroepiandrosterone and coronary atherosclerosis. Ann N Y Acad Sci (1995) 0.84
Serum dehydroepiandrosterone sulfate concentrations in men with erectile dysfunction. Urology (2000) 0.84
Dehydroepiandrosterone sulfate is inversely associated with sex-dependent diverse carotid atherosclerosis regardless of endothelial function. Atherosclerosis (2010) 0.84
Dehydroepiandrosterone replacement in healthy men with age-related decline of DHEA-S: effects on fat distribution, insulin sensitivity and lipid metabolism. Aging Male (2003) 0.84
Effects of dehydroepiandrosterone replacement on vascular function in primary and secondary adrenal insufficiency: a randomized crossover trial. J Clin Endocrinol Metab (2009) 0.84
Inhibition of accelerated coronary atherosclerosis with dehydroepiandrosterone in the heterotopic rabbit model of cardiac transplantation. Circulation (1993) 0.84
Possible association of heart failure status with synthetic balance between aldosterone and dehydroepiandrosterone in human heart. Circulation (2004) 0.83
Might DHEA be considered a beneficial replacement therapy in the elderly? Drugs Aging (2007) 0.83
DHEA for postmenopausal women: a review of the evidence. Maturitas (2010) 0.83
Prevalence and predictors of sexual problems in men aged 75-95 years: a population-based study. J Sex Med (2011) 0.82
DHEA metabolism in prostate: For better or worse? Mol Cell Endocrinol (2008) 0.82
A multiplicity of approaches to characterize geriatric depression and its outcomes. Curr Opin Psychiatry (2009) 0.82
A view of geriatrics through hormones. What is the relation between andropause and well-known geriatric syndromes? Maturitas (2012) 0.82
Older patients in the emergency department: a review. Ann Emerg Med (2010) 2.06
Circadian clock characteristics are altered in human thyroid malignant nodules. J Clin Endocrinol Metab (2013) 1.47
Agenesis of human pancreas due to decreased half-life of insulin promoter factor 1. J Clin Endocrinol Metab (2003) 1.41
The metabolic syndrome and type 2 diabetes: epidemiological figures and country specificities. Cerebrovasc Dis (2005) 1.25
Pain in severe dementia: self-assessment or observational scales? J Am Geriatr Soc (2006) 1.09
Pax6 controls the expression of critical genes involved in pancreatic {alpha} cell differentiation and function. J Biol Chem (2010) 1.07
Pax6 is crucial for β-cell function, insulin biosynthesis, and glucose-induced insulin secretion. Mol Endocrinol (2012) 1.06
Pax-6 and c-Maf functionally interact with the alpha-cell-specific DNA element G1 in vivo to promote glucagon gene expression. J Biol Chem (2007) 1.04
Hepatic nuclear factor-3 (HNF-3 or Foxa2) regulates glucagon gene transcription by binding to the G1 and G2 promoter elements. Mol Endocrinol (2002) 1.02
Antidiabetic drugs and kidney disease--recommendations of the Swiss Society for Endocrinology and Diabetology. Swiss Med Wkly (2012) 0.96
The zinc finger-containing transcription factor Gata-4 is expressed in the developing endocrine pancreas and activates glucagon gene expression. Mol Endocrinol (2004) 0.94
Pax6 regulates the proglucagon processing enzyme PC2 and its chaperone 7B2. Mol Cell Biol (2009) 0.92
Biological rhythms and preeclampsia. Front Endocrinol (Lausanne) (2013) 0.87
Severe congenital hyperinsulinism caused by a mutation in the Kir6.2 subunit of the adenosine triphosphate-sensitive potassium channel impairing trafficking and function. J Clin Endocrinol Metab (2005) 0.86
Glucagon responses of isolated α cells to glucose, insulin, somatostatin, and leptin. Endocr Pract (2011) 0.85
The beta-cell specific transcription factor Nkx6.1 inhibits glucagon gene transcription by interfering with Pax6. Biochem J (2007) 0.85
Activin A decreases glucagon and arx gene expression in alpha-cell lines. Mol Endocrinol (2006) 0.84
Pax2 mutant mice display increased number and size of islets of Langerhans but no change in insulin and glucagon content. Eur J Endocrinol (2004) 0.82
Islet autotransplantation after left pancreatectomy for non-enucleable insulinoma. Am J Transplant (2003) 0.82
Effects of widely used drugs on micronutrients: a story rarely told. Nutrition (2013) 0.82
Molecular detection of circulating beta-cells after islet transplantation. Diabetes (2002) 0.81
Pax6 is a key component of regulated glucagon secretion. Endocrinology (2012) 0.81
Essential interaction of Egr-1 at an islet-specific response element for basal and gastrin-dependent glucagon gene transactivation in pancreatic alpha-cells. J Biol Chem (2004) 0.81
Testosterone replacement therapy in reversing "andropause": what is the proof-of-principle? Rejuvenation Res (2012) 0.80
Influenza vaccination in the face of immune exhaustion: is herd immunity effective for protecting the elderly? Influenza Res Treat (2012) 0.79
[Chronic liver diseases and diabetes]. Rev Med Suisse (2014) 0.79
Aging adults and seasonal influenza: does the vitamin d status (h)arm the body? J Aging Res (2011) 0.78
Swiss Hypertension and Risk Factor Program (SHARP): cardiovascular risk factors management in patients with type 2 diabetes in Switzerland. Blood Press (2005) 0.78
Insulin independence after conversion to tacrolimus and sirolimus-based immunosuppression in islet-kidney recipients. Transplantation (2003) 0.78
Transcatheter aortic valve implantation in nonagenarians: effective and safe. Eur J Intern Med (2013) 0.78
Glucagon: the renewal of an old hormone in the pathophysiology of diabetes. J Diabetes (2013) 0.77
Multislice gated-computed tomography of cardiac paragangliomas. J Am Coll Cardiol (2010) 0.77
Foxa1 and Foxa2 regulate α-cell differentiation, glucagon biosynthesis, and secretion. Endocrinology (2014) 0.77
The prognostic significance of malnutrition as assessed by the Mini Nutritional Assessment (MNA) in older hospitalized patients with a heavy disease burden. Clin Nutr (2011) 0.76
The Hospital Anxiety and Depression Scale: low sensitivity for depression screening in demented and non-demented hospitalized elderly. Int Psychogeriatr (2012) 0.76
Free Fatty Acids Impair FGF21 Action in HepG2 Cells. Cell Physiol Biochem (2015) 0.76
A rare case of adrenal insufficiency induced by inhaled corticosteroids. J Am Geriatr Soc (2013) 0.76
[Diabetes and cancer: an injurious association]. Rev Med Suisse (2010) 0.76
Comparison of the interobserver variability of 2 different methods of dietary assessment in a geriatric ward: a pilot study. J Am Med Dir Assoc (2011) 0.75
Left atrial myxoma: a rare but treatable source of systemic emboli in older patients. J Am Geriatr Soc (2009) 0.75
[Diabetes and non-alcoholic fatty liver disease]. Rev Med Suisse (2012) 0.75
[The evolution of obesity]. Rev Med Suisse (2005) 0.75
Subcutaneous migration of a central venous catheter. Clin Nutr (2012) 0.75
[Polycystic ovaries: what's news in 2015?]. Rev Med Suisse (2015) 0.75
[Dementia prevention: potential treatments and how to target high risk patients]. Rev Med Suisse (2013) 0.75
Transcatheter aortic valve implantation in a 99-year-old woman: are we going too far? J Am Geriatr Soc (2012) 0.75
[Diabetes in 2015: constantly increasing, but with enlarged therapeutics options]. Rev Med Suisse (2015) 0.75
[Which insulin for which patients in 2014]. Rev Med Suisse (2014) 0.75
[News in diabetology]. Rev Med Suisse (2015) 0.75
[Iodine excess induced thyroid dysfunction]. Rev Med Suisse (2016) 0.75
Giant mucinous ovarian tumor. Am J Med Sci (2013) 0.75
[Physical activity in the prevention and control of diabetes]. Rev Med Suisse (2007) 0.75
An unusual case of cholecystitis and liver abscesses in an older adult. J Am Geriatr Soc (2012) 0.75
[GLP-1 receptor agonists versus SGLT-2 inhibitors in obese type 2 diabetes patients]. Rev Med Suisse (2015) 0.75
Mycobacterial arthritis. J Am Geriatr Soc (2012) 0.75
[Management of diabetes: a priority for the European Union]. Rev Med Suisse (2006) 0.75
[Not Available]. Rev Med Suisse (2016) 0.75
[Why is managing diabetic patients so difficult?]. Rev Med Suisse (2009) 0.75
[Combined treatment of insulin and GLP-1 analogs: what do we expect?]. Rev Med Suisse (2014) 0.75
[Insulin and oral antidiabetes drugs: how associate these treatments in ambulatory care?]. Rev Med Suisse (2016) 0.75
[Prevention and remission of diabetes: is it feasible?]. Rev Med Suisse (2016) 0.75
[The clinical path concept or the difficult revolution of chronic diseases management]. Rev Med Suisse (2014) 0.75
[Sleep and diabetes]. Rev Med Suisse (2012) 0.75
[Personalized medicine is the far side of the moon]. Rev Med Suisse (2012) 0.75
[Age related dehydroepiandrosterone decrease: clinical significance and therapeutic interest]. Rev Med Suisse (2015) 0.75
[Insulin and cancer: myth or reality?]. Rev Med Suisse (2010) 0.75
[Aspirin as primary prevention for diabetic patients]. Rev Med Suisse (2010) 0.75
Cauliflower bowel: a tumor-induced mesenteric retraction. Am J Med Sci (2014) 0.75
[Type 1 or 2 diabetes? Or other?]. Rev Med Suisse (2009) 0.75